News

AgroSpheres and BASF Announce Major Strategic Partnership

AgroSpheres, a biotechnology leader in sustainable crop protection and crop health, and BASF, a global leader in agricultural solutions, are excited to announce their strategic partnership on a category defining novel bioinsecticide. This collaboration marks a significant step forward in sustainable agriculture solutions aimed at enhancing crop protection.

The companies are working together to develop biological crop protection products leveraging AgroSpheres AgriCell-powered biomolecules. Both companies are encouraged by the levels of efficacy that have been demonstrated at low dose rates to control key agricultural lepidopteran pests. Both companies are committed to working together to develop innovative and sustainable crop protection products that will increase the choices available to farmers to manage pests and support optimal productivity.

Payam Pourtaheri, CoFounder and CEO of AgroSpheres, stated, “Our partnership with BASF exemplifies the synergy that can be achieved when innovative biotech meets extensive agricultural expertise. The results of our bioinsecticide development are extremely promising, and we are eager to continue our work together to bring effective solutions to farmers worldwide.”

Ameer Shakeel, CoFounder and CTO of AgroSpheres, added, “This collaboration is a testament to our team’s ability to develop novel biomolecules, amplify them with the AgriCell and forge strategic partnerships to reach farmers around the world. We are proud to partner with BASF and are excited about the potential impact of our partnership.”

Both companies are committed to furthering their research and development efforts, with plans to accelerate the development of this product line and launch a pipeline powered by the AgriCell.

Stephanie Jensen, Vice President, Crop System Rice and Portfolio Solutions Insecticides and Seed Treatment, BASF Agricultural Solutions, concluded, “We are incredibly encouraged by the results we’ve achieved thus far and by the potential impact for our customers from this innovative technology. Moving forward, our focus remains on delivering a bioinsecticide that adds genuine value for farmers, promoting higher yields and healthier crops.”

Stefan Tresch, Head of New Technologies & BioSolutions at BASF Agricultural Solutions, remarked, “BASF is dedicated to developing innovative solutions that provide added benefit to our agricultural customers, and we believe in the unique value represented by the AgriCell platform. AgroSpheres has showcased some of the most promising biomolecules we’ve encountered. Our collaboration with AgroSpheres is a testament to the power of partnerships in driving innovation.”

Both AgroSpheres and BASF are dedicated to fostering a sustainable agricultural ecosystem, and this partnership is a crucial step in that journey.

 

Learn more here.

Recent News

03/12/2026

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare

03/11/2026

ATCC Secures NIAID Contract to Strengthen U.S. Preparedness Against Emerging Infectious Diseases

ATCC has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract (number 75N93025D00017) with an ordering period of 7 years with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS). The contract, with an initial

03/10/2026

ivWatch and Aon Address Costly and Underreported Patient Harm Epidemic with New Return on Investment Model

ivWatch, the IV safety company, has partnered with Aon, a leading global insurance broker and risk consultant, to quantify the clinical and financial impact of severe IV infiltration and extravasation injuries – one of the most underreported and costly adverse events in healthcare – and to model the return on investment associated with detecting these